



Disruptive technology: Streamlined Access to Papers (SAP)

Amanda Burls

9th International Conference for EBHC Teachers and Developers, Taormina, Sicily
November 2019



Yesterday Gordon Guyatt told us:

- Be realistic
- Clinician's won't read methods and results

No time

What is the doubling time of medical knowledge?

- In 2020 projected to be 73 days!
- What you learnt in your first 3 years of medical school will be just 6% of what is known at the end 2020.





Alessandro Liberati –

Could a second transplant improve results?



“... as a patient I felt even more strongly about what I’ve been fighting for throughout my career. Research results should be easily accessible to people who need to make decisions about their own health. The delay in the combined analysis of the four randomised controlled trials struck me as a case in point. Why was I forced to make my decision knowing that information was somewhere but not available?”

An unfinished trip through uncertainties

BMJ 2004 ; 328 doi:https://doi.org/10.1136/bmj.328.7438.531 (Published 26 February 2004)

Cite this as: BMJ 2004;328:531

- Article
- Related content
- Metrics
- Responses

Alessandro Liberati, associate professor of medical biostatistics (alesslib@tin.it)

Author affiliations ▾

In mid-1997 I went for blood and other tests after an episode of back pain. A monoclonal electrophoretic peak and a spinal lesion of uncertain origin were found. After a few months of further tests I was given a diagnosis of monoclonal gammopathy of uncertain significance (MGUS). I was no longer a subjectively healthy man but a potentially ill person, with considerable anxiety. MGUS is one of those strange noso-logical entities of modern medicine—which is so good at creating “new diseases” without necessarily knowing how to cure them. The medical literature didn't help much. Several small studies reported a cumulative risk of malignant transformation of MGUSs of between 7% and 19%, with the likeliest estimate of annual risk of transformation around 1%, but without clear predictors.

“ **Could a second transplant improve results?**

I was prescribed blood tests every six months to monitor any such transformation. The years went by, during which my levels of anxiety varied, increasing at times of testing and whenever any personal or work ...

[View Full Text](#)


Log in

[BMA Member Log In](#)

Subscribe from £138 *

Subscribe and get access to all BMJ articles, and much more.

[Subscribe](#)



Worldwide inequality in access to full text scientific articles: the example of ophthalmology.
 October 30th 2019
<https://peerj.com/articles/7850/>



Alexandra Elbakyan

A photograph of ocean waves with white foam, set against a blue background that transitions into a solid blue gradient.

“The most important thing you taught us...”

www.Sci-Hub.tw




SCI-HUB

...to remove all barriers in the way of science



the first website in the world to provide mass & public access to research papers



thebmj Research Education News & Views Campaigns Archive

An unfinished trip through uncertainties

BMJ 2004 ; 328 : 328-331. doi: <https://doi.org/10.1136/bmj.328.7438.531> (Published 26 February 2004)
Cite this as: *BMJ* 2004;328:531

Article Related content Metrics Responses

Alessandro Liberati, associate professor of medical biostatistics (alesslib@tin.it)

[Author affiliations](#)

In mid-1997 I went for blood and other tests after an episode of back pain. A monoclonal electrophoretic peak and a spinal lesion of uncertain origin were found. After a few months of further tests I was given a diagnosis of monoclonal gammopathy of uncertain significance (MGUS). I was no longer a subjectively healthy man but a potentially ill person, with considerable anxiety. MGUS is one of those strange noso-logical entities of modern medicine—which is so good at creating “new diseases” without necessarily knowing how to cure them. The medical literature didn't help much. Several small studies reported a cumulative risk of malignant transformation of MGUSs of between 7% and 19%, with the likeliest estimate of annual risk of transformation around 1%, but without clear predictors.

“ Could a second transplant improve results?

I was prescribed blood tests every six months to monitor any such transformation. The years went by, during which my levels of anxiety varied, increasing at times of testing and whenever any personal or work ...

[View Full Text](#)

Log in

BMA Member Log In

Subscribe from £138 *

Subscribe and get access to all BMJ articles, and much more.

Subscribe




SCI-HUB


...to remove all barriers in the way of science

doi: <https://doi.org/10.1136/bmj.328.7438.531>



the first website in the world to provide mass & public access to research papers





Sci-Hub: The new and ultimate disruptor?
View from the front. Nicholas, D. et al
2018. doi:10.1002/leap.1206

Is it wrong?

“... digital piracy ... is arguably ... an act that is technically illegal but not morally wrong.... what’s genuinely wrong is restricting access to knowledge; copyright piracy as a method of opening up access to knowledge is not ‘wrong’ – it’s merely illegal”



Research: Sci-Hub provides access to nearly all scholarly literature, Himmelstein et al 2018, eLife 2018;7:e32822

“...use of Sci-Hub may constitute copyright infringement. Users of Sci-Hub do so at their own risk. This study is not an endorsement of using Sci-Hub, and its authors and publishers accept no responsibility on behalf of readers. There is a possibility that Sci-Hub users—especially those not using privacy-enhancing services such as Tor—could have their usage history unmasked and face consequences, both legal or reputational in nature.”

The image features a top-down view of ocean waves with white foam, set against a dark blue background that transitions into a lighter blue gradient. The text is overlaid on this background.

@lukeweston

*“I wonder how many dollars of economic value have been enabled because of **sci-hub**? How many lives have been indirectly saved, because of **sci-hub**?”*

acute heart failure

36208 Results Evidence Type ▾

18. Acute heart failure: diagnosis and management

National Institute for Health and Clinical Excellence - Clinical Guidelines 2014

19. Clinical characteristics and outcomes of Yemeni patients with acute heart failure aged 50years or younger: Data from Gulf Acute Heart Failure Registry (Gulf CARE).

International journal of cardiology 2016

20. Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure).

Circulation. Heart failure 2016

21. Predicting Risk in Patients Hospitalized for Acute Decompensated Heart Failure and Preserved Ejection Fraction: The Atherosclerosis Risk in Communities Study Heart Failure Community Surveillance.

Circulation. Heart failure 2017

www.BestEvidence.Info



An open database of 24,620,415 free scholarly articles.

We harvest Open Access content from over 50,000 publishers and repositories, and make it easy to find, track, and use.

LEARN MORE

GET THE EXTENSION

An unfinished trip through uncertainties

BMJ 2004 ; 328 doi: <https://doi.org/10.1136/bmj.328.7438.531> (Published 26 February 2004)

Cite this as: BMJ 2004;328:531

[Article](#)
[Related content](#)
[Metrics](#)
[Responses](#)

Alessandra Liberati, associate professor of medical biostatistics (alesslib@tin.it)

[Author affiliations ▾](#)

In mid-1997 I went for blood and other tests after an episode of back pain. A monoclonal electrophoretic peak and a spinal lesion of uncertain origin were found. After a few months of further tests I was given a diagnosis of monoclonal gammopathy of uncertain significance (MGUS). I was no longer a subjectively healthy man but a potentially ill person, with considerable anxiety. MGUS is one of those strange noso-logical entities of modern medicine—which is so good at creating “new diseases” without necessarily knowing how to cure them. The medical literature didn’t help much. Several small studies reported a cumulative risk of malignant transformation of MGUSs of between 7% and 19%, with the likeliest estimate of annual risk of transformation around 1%, but without clear predictors.



Could a second transplant improve results?

I was prescribed blood tests every six months to monitor any such transformation. The years went by, during which my levels of anxiety varied, increasing at times of testing and whenever any personal or work ...

[View Full Text](#)

Log in

[BMA Member Log In](#)

If you have a subscription to The BMJ, log in:

Username

Subscribe from £138 *

Subscribe and get access to all BMJ articles, and much more.

[Subscribe](#)

* For online subscription

Article tools

4 responses

Respond to this article

Print

Alerts & updates ▾

Citation tools ▾

Request permissions

Author citation ▾

Add article to BMJ Portfolio

Email to a friend ▾

UK jobs

International jobs

Mitcham Medical Centre: Salaried GP


St George's University Hospitals NHS Foundation Trust: Locum Consultant in Medical Oncology specialist interest in Melanoma

St George's University Hospitals NHS Foundation Trust: Locum Consultant Haematologist


DeMontfort Medical Centre: Partnership/Salaried with a View to Partnership

Southern Health NHS Foundation Trust: Consultant Geriatrician

Improving BestEvidence

- Provide one-click access to Open Access papers using UnPayWall API
-  Why not allow users to put in their institutional IDs and also provide one click access to full paper?

Brainwave? Really?




Stop clicking and start reading.

Save time navigating paywalls, logins and redirects. Kopernio helps you get to your full-text PDF faster.

With Kopernio

One click PDF access



Without Kopernio

Lots of clicking, logins, redirects, and annoyance



Reviews » PERSONAL VIEW

An unfinished trip through uncertainties

BMJ 2004 ; 328 doi: <https://doi.org/10.1136/bmj.328.7438.531> (Published 26 February 2004)

Cite this as: *BMJ* 2004;328:531

Article Related content Metrics Responses

Alessandro Liberati, associate professor of medical biostatistics (alesslib@tin.it)

Author affiliations

In mid-1997 I went for blood and other tests after an episode of back pain. A monoclonal electrophoretic peak and a spinal lesion of uncertain origin were found. After a few months of further tests I was given a diagnosis of monoclonal gammopathy of uncertain significance (MGUS). I was no longer a subjectively healthy man but a potentially ill person, with considerable anxiety. MGUS is one of those strange noso-logical entities of modern medicine—which is so good at creating “new diseases” without necessarily knowing how to cure them. The medical literature didn't help much. Several small studies reported a cumulative risk of malignant transformation of MGUSs of between 7% and 19%, with the likeliest estimate of annual risk of transformation around 1%, but without

Article tools

- 4 responses
- Respond to this article
- Print
- Alerts & updates
- Citation tools
- Request permissions
- Author citation
- Add article to BMJ Portfolio
- Email to a friend





Kopernio - limitation

- One institutional ID only (I have 5!)
- Won't work on a smartphone or mobile device
- Freedom to operate

- <https://kopernio.com/invite/71433809>

A photograph of ocean waves with white foam, set against a blue background that transitions into a solid blue gradient.

Streamlined Access to Papers (SAP)

Sci-hub = Napster

SAP = Spotify

- Work on mobile device and integrates into BestEvidence app

1990

X

